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This article reviews the effectiveness of Kampo (traditional Japanese herbal medicine) in the treatment of functional
gastrointestinal disorders, especially functional dyspepsia (FD) and irritable bowel syndrome (IBS). The results of four
randomized, controlled trials (RCTs) suggested the usefulness of rikkunshito in relieving the subjective symptoms of
patients with FD. Rikkunshito significantly improved not only gastric symptoms, such as epigastiric discomfort, but
also extra-gastric symptoms, such as general fatigue, when compared with control drugs. The therapeutic effects of
rikkunshito were more evident when it was prescribed to patients with “kyosho”, i.e., low energy. Two RCTs suggested
the efficacy of keishikashakuyakuto for IBS.
Basic research studies have demonstrated that these Kampo medicines have multiple sites of action to improve
subjective symptoms. For example, rikkunshito improves gastric motility dysfunction, including impaired adaptive
relaxation and delayed gastric emptying, gastric hypersensitivity, and anorexia via facilitation of ghrelin secretion. It also
exhibits anti-stress effects, i.e., it attenuates stress-induced exacerbation of gastric sensation and anorexia, as well as the
hypothalamic-pituitary-adrenocortical axis and sympathetic activation. Keishikashakuyakuto exhibited not only an
antispasmodic effect on intestinal smooth muscle, but also antidepressant-like effects. Case series suggest that
other Kampo prescriptions are also effective for FD and IBS. However, further studies are necessary to evaluate
their efficacy.
Keywords: Kampo, Rikkunshito, Keishikashakuyakuto, Functional dyspepsia, Irritable bowel syndromeKampo refers to Japanese traditional medicine, including
herbal medicine. In Japan, herbal medicine is very popu-
lar, and it is covered by national health insurance. Psy-
chosomatic medicine specialists often prescribe Kampo
medicines to treat functional somatic diseases, such as
functional gastrointestinal disorders (FGIDs). Patients
with FGIDs complain of symptoms originating from the
gastrointestinal tract without evident organic diseases.
These symptoms are bothersome for patients and
difficult to treat, thus decreasing patient quality of life.
The pathophysiology of FGIDs is multifactorial. Both
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reproduction in any medium, provided the orhypersensitivity, inflammation, and altered bacterial flora,
as well as psychosocial factors, including psychological
stress, psychological state, coping style, and social support
affect brain-gut interactions and clinical outcomes [1,2].
Currently, many Kampo formulas are prescribed to
treat FGIDs. However, the evidence of their efficacy is
limited. Furthermore, as many earlier studies conducted
in the 1980’s and 90’s were published in Japanese, those
pioneering works have not been introduced into the
English literature or indexed in PubMed.
Therefore, the aims of this paper are (1) to review the
clinical trials that investigated the effect of Kampo on
FGIDs, including studies published in Japanese, and (2)
to provide an overview of the basic mechanisms as to
how Kampo improves the subjective symptoms of pa-
tients with FGIDs, focusing on functional dyspepsia (FD)
and irritable bowel syndrome (IBS).. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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We performed literature searches on PubMed and Ichushi
Web (papers written in Japanese) on June 30, 2013 using
the keywords Kampo (or each prescription name) and
functional dyspepsia or irritable bowel syndrome. We in-
cluded reports regarding Kampo extract products that
comply with the formulation standards established in
1986 and excluded those regarding drug solutions of
crude drug pieces for decoction, powdered crude drugs,
and over the counter (OTC) products. We abstracted clin-
ical studies conducted as randomized, controlled trials
(RCTs) and case series that involved at least 10 cases. We
present the results descriptively, because a meta-analysis
was not possible due to the limited number of RCTs. We
also introduce basic research findings to explain the pos-
sible mechanisms of action of each Kampo medicine.
Results
Functional dyspepsia
To date, four RCTs, including one double blind (DB)-
RCT and 13 case series have been published. All studies
were conducted in Japan. Most of them, especially all of
the RCTs, studied the effectiveness of rikkunshito on
dyspeptic symptoms. In these studies, the diagnosis of
FD was based on either the American Gastroenterology
Association working party criteria, in which the condi-
tion is named non-ulcer dyspepsia [3], or the Rome III
diagnostic criteria, in which the condition is named FD
[4]. In this analysis, we included both.
Efficacy of rikkunshito
According to the traditional medicine point of view, rik-
kunshito is a Kampo medicine for treating upper gastro-
intestinal symptoms, such as nausea, indigestion, and
anorexia in patients with “kyo-sho”, i.e., subjects who
have weak constitutions and low vital energy. Rikkun-
shito extract granules for ethical use (Tsumura and Co.,
Product number TJ-43) (7.5 g) contain 4.0 g of dried ex-
tract obtained from mixed raw herbs in the following ra-
tio: Atractylodes Lancea Rhizome, 4.0 g; Ginseng, 4.0 g;
Pinellia Tuber, 4.0 g; Poria Sclerotium, 4.0 g; Jujube,
2.0 g; Citrus Unshiu Peel, 2.0 g; Glycyrrhiza, 1.0 g; and
Ginger, 0.5 g.
Miyoshi and colleagues conducted the first multi-center
RCT to compare the therapeutic effects of rikkunshito
and cisapride, a prokinetic drug, on the digestive symp-
toms of patients with non-ulcer dyspepsia. Subjects were
randomized to receive either oral treatment with 2.5 g rik-
kunshito three times daily (rikkunshito group, 111 sub-
jects) or cisapride (2.5 mg) three times daily (cisapride
group, 104 subjects) for four weeks. Significantly greater
improvement of upper gastrointestinal symptoms, espe-
cially epigastralgia and abdominal discomfort, was found
for rikkunshito than for cisapride [5]. Rikkunshito alsoresulted in greater, but non-significant, improvement of
extra-gastric symptoms, such as coldness in the lower ex-
tremities, dizziness, and appetite loss when compared with
cisapride. The global improvement rate of the rikkunshito
group was higher than that of the cisapride group when
this Kampo medicine was prescribed to subjects whose
constitutions were weak or who felt moderate general fa-
tigue, i.e., subjects with “kyo-sho”.
Harasawa and coworkers conducted a multi-center DB-
RCT to assess the effect of rikkunshito on dismotility-like
dyspepsia [6], one subtype of FD defined by the Rome II
diagnostic criteria. Subjects were randomized to receive
either oral treatment with 2.5 g rikkunshito three times
daily (rikkunshito group, 133 subjects) or 2.5-g granules
containing a low dose (2.5%) of rikkunshito three times
daily as a control (control group, 117 subjects) for two
weeks. Rikkunshito significantly improved the dysmotility-
like dyspepsia generalized improvement rate (DDGIR) and
subjective symptoms, including epigastric discomfort, an-
orexia and, interestingly, general fatigue [7] when com-
pared with the control group. In the rikkunshito group,
the DDGIR improved more in patients whose vigor or
physical strength was low when compared with those
whose energy or strength was normal. The incidence of
adverse events was not different between the two groups,
i.e., adverse events were reported by seven subjects in the
rikkunshito group and seven subjects in the control group.
The most frequently observed adverse symptom was diar-
rhea (3 subjects in each group). The results of these two
RCTs suggested the effectiveness of rikkunshito for FD.
Furthermore, these studies also suggested that rikkunshito
is more effective when it is prescribed to subjects with
“kyo-sho”, based on the traditional medicine diagnosis in
patients with FD. These findings were published in
Japanese.
Tatsuta and colleagues investigated the effects of rik-
kunshito on gastric emptying as well as the gastrointes-
tinal symptoms of 42 dyspeptic patients in a RCT and
first reported their findings in English [8]. In this study,
by random allocation, 22 patients received oral treat-
ment with 2.5 g rikkunshito three times daily, and 20 pa-
tients received combizym as a placebo. Gastric emptying
was measured by the acetaminophen absorption method.
After seven days of treatment, gastric emptying was signifi-
cantly accelerated, and gastrointestinal symptoms, such as
epigastric fullness, heartburn, belching, and nausea, were
significantly improved in patients treated with rikkunshito.
In contrast, placebo treatment produced no significant ef-
fects on gastric emptying and subjective symptoms.
Arai and colleagues compared the effects of four
weeks of treatment with rikkunshito or domperidone, a
prokinetic drug, on the gastrointestinal symptoms of 27
patients with FD in a RCT and found that dyspeptic
symptoms improved significantly in both groups [9].
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shito is a useful drug for treating FD. Two RCTs sug-
gested that the therapeutic effect of rikkunshito on FD
was stronger when it is prescribed to subjects with
“kyo-sho”, based on the traditional medicine diagnosis.
There were 13 case series. Most of them reported the
effectiveness of rikkunshito. Other studies suggested
the effectiveness of hangekobokuto [10,11] and hange-
shashinto. Notably, two studies suggested that hange-
shashinto is effective for dyspeptic patients for whom
in rikkunshito was not effective [12,13].
Therapeutic mechanisms of rikkunshito
The subjective symptoms of FD are attributed to disturbed
gastric motility and gastric hypersensitivity [4,14]. Psycho-
logical stress affects gastric motility [15] and gastric sensi-
tivity [16,17] and causes or exacerbates FD symptoms [18].
Some patients with FD suffer from co-morbid psychiatric
disorders, such as depressive and anxiety disorders [18-20].
Any or all of these components may contribute to the de-
velopment of subjective symptoms in patients with FD
[20,21]. Human and animal studies have shown that rik-
kunshito has effects on each of these factors.
Gastric motility dysfunction
In patients with FD, gastric motility functions, such as
gastric adaptive relaxation (or gastric accommodation)
and gastric emptying, are impaired.
Gastric emptying
Harasawa and coworkers have demonstrated that a two-
week administration of rikkunshito accelerated gastric
emptying, as assessed by the acetaminophen absorption
method, and improved upper gastrointestinal symptoms
in patients with FD whose gastric emptying was delayed
[22]. Tatsuta and coworkers also reported that rikkunshito
improved gastric emptying in patients with FD [8]. Animal
studies have suggested that rikkunshito accelerates gastric
emptying [8,22] via nitric oxide-mediated mechanisms
[23] and antagonism of 5-HT3 receptors [24].
Adaptive relaxation
Two weeks of rikkunshito administration significantly
expanded the proximal stomach after incremental inges-
tion of a liquid meal up to 400 mL in patients with FD,
suggesting that rikkunshito promotes gastric adaptive re-
laxation [25], a finding that had been observed in animal
models [26,27].
Other motility functions
Rikkunshito was also reported to coordinate gastric
myoelectric activity in patients with dyspeptic symptoms
after gastrointestinal surgery [28] and to stimulate gastro-
intestinal motility in dogs [29,30].Gastric hypersensitivity
The effect of rikkunshito on gastric hypersensitivity has
not yet been investigated in patients with FD. However,
in healthy subjects, rikkunshito was reported to reduce
epigastric fullness following gastric distension via a gas-
tric barostat. Rikkunshito also attenuated psychological
stress-induced reduction of gastric volume at the sen-
sory threshold and stress-induced increased anxiety at
the discomfort threshold [31], suggesting that rikkun-
shito improves gastric symptoms under distension, pos-
sibly by affecting gastric sensorimotor function.
Ghrelin secretion
Ghrelin is a 28-amino acid orexigenic peptide found in
the stomach [32]. Takeda and colleagues demonstrated
that rikkunshito suppresses cisplatin-induced decreases
in plasma levels of acylated ghrelin, an active form of
ghrelin, and that it increases food intake via serotonin
(5-HT) 2B/2C receptor antagonism in rats [33]. After
that report, research intensified to determine whether
rikkunshito increases ghrelin secretion in human sub-
jects, leading to improvement of appetite and dyspeptic
symptoms (for review, see [34]). Oral administration of
rikkunshito for two or four weeks has been demon-
strated to increase plasma levels of acylated ghrelin in
healthy subjects [35], patients with gastric cancer [36],
and patients with FD [9]. Arai and coworkers compared
the effects of rikkunshito with the effect of domperidone
on plasma ghrelin levels and gastrointestinal symptoms in
patients with FD. Four weeks after treatment, the plasma
level of acylated ghrelin in the rikkunshito group was sig-
nificantly higher than that in the domperidone group,
whereas the plasma level of desacylated ghrelin, an in-
active form of ghrelin, was not different between the two
groups [9]. Furthermore, in the rikkunshito group, the im-
provements in reflux and indigestion showed positive cor-
relations with the increase in acylated ghrelin. Among the
eight ingredients of rikkunshito, flavonoids of citrus
unshiu peel, i.e., heptamethoxyflavone and hesperidin,
and flavonoids of glycyrrhiza, i.e., isoliquiritigenin have
5-HT2B antagonist activity and reverse the cisplatin-
induced suppression of plasma acylated ghrelin [33]; and
atractylodin, a component of the Atractylodes Lancea
Rhizome, potentiates ghrelin receptor signaling [37].
These findings suggest that rikkunshito improves the
subjective symptoms of FD, at least in part, by facilitat-
ing the secretion of ghrelin.
Psychological factors and stress
We assessed the effect of 4 weeks of rikkunshito admin-
istration on depressive symptoms in patients with FD.
Rikkunshito significantly decreased depression scores, as
assessed by the Self-Rating Questionnaire for Depression
[38]. As depressed patients frequently show high serum
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weeks of rikkunshito administration on serum cortisol
levels at 9 a.m. in patients with FD [39]. Seven of 23 pa-
tients showed levels higher than the normal range. Four
weeks of rikkunshito administration significantly de-
creased their cortisol levels, whereas rikkunshito did not
affect the cortisol levels of patients with levels in the
normal range. An animal study has demonstrated that
rikkunshito attenuates the activities of corticotropin-
releasing hormone (CRH)-producing neurons and reduces
anxiety-like behavior in tumor-bearing rats. As cancer-
induced anorexia and cachexia are induced by 5-HT2c
receptor-mediated interactions of 5-HT with CRH-
producing neurons and CRH activates the hypothalamic-
pituitary-adrenocortical (HPA) axis, decreases the plasma
levels of acylated ghrelin, and induces anxiety-like behav-
ior, the inhibitory effect of rikkunshito on CRH-producing
neurons may contribute to psychological effects and
normalization of high cortisol levels [37].
Rikkunshito was also shown to attenuate stress-induced
physiological responses. For example, rikkunshito attenuated
acute stress-induced increases in plasma levels of adrenocor-
ticotropic hormone, cortisol [40], and neuropeptide Y [41]
evoked by repeated blood sampling in healthy subjects. As
neuropeptide Y and noradrenaline are coreleased from the
sympathetic nerve terminals by activation of the sympathetic
nervous system and are released into plasma during inten-
sive sympathetic activation, neuropeptide Y is consid-
ered a marker of stress-induced sympathetic activation.
In addition to its inhibitory effect on the stress-induced
activation of the HPA axis and the sympathetic nervous
system, rikkunshito improved the delayed gastrointestinal
tract motility induced by stress mimicking a Japanese
summer, i.e., high temperature and humidity stress in
mice [42]. Rikkunshito also reversed the stress-induced re-
duction of intragastric volume stimulated by a barostat at
the sensory threshold in healthy subjects [31]. Further-
more, rikkunshito reversed the novelty stress-induced re-
duction in food intake via ghrelin secretion in rats [43].
Based on these findings, “A Guideline for the Diagnosis
and Treatment of Psychosomatic Diseases 2006” recom-
mends prescription of rikkunshito for treating FD [44].
Furthermore, rikkunshito is widely prescribed for treating
the upper gastrointestinal tract symptoms of patients with
gastroesophageal reflux disease [45-47], gastric cancer
[36], patients who underwent gastrointestinal surgery [28]
or chemotherapy [48,49], and patients who take selective
serotonin reuptake inhibitors [50]. Rikkunshito is also
thought to be a promising drug for ameliorating anorexia-
cachexia in patients with cancer [37].
Irritable bowel syndrome
To date, two RCTs, including one DB-RCT and 14 case
series have been published. All studies were conductedin Japan and published in Japanese. Two RCTs studied
the effectiveness of keishikashakuyakuto on IBS [51,52].
Efficacy of keishikashakuyakuto
Keishikashakuyakuto is a Kampo medicine that is pre-
scribed to relieve abdominal pain. Keishikashakuyakuto
extract granules for ethical use (Tsumura and Co., Prod-
uct number TJ-60) (7.5 g) contain 3.75 g of dried extract
obtained from mixed raw herbs in the following ratio:
Peony root, 6.0 g; Cinnamon Bark, 4.0 g; Jujube Fruit,
4.0 g; Glycyrrhiza Root, 2.0 g; and Ginger Rhizome,
1.0 g.
Mizuno and colleagues conducted the first RCT to com-
pare the therapeutic effect of keishikashakuyakuto with
mepenzolate bromide, an anti-cholinergic agent, on IBS.
Subjects were randomized to receive either oral treatment
with 2.5 g keishikashakuyakuto three times daily (keishika-
shakuyakuto group, 26 subjects) or mepenzolate bromide
(15 mg) three times daily (mepenzolate group, 24 subjects)
for eight weeks. At four weeks after the start of treatment,
the keishikashakuyakuto group had significantly greater
improvement than mepenzolate of IBS symptoms, includ-
ing stool abnormality, abdominal pain, gas symptoms, and
rumbling stomach. The final overall improvement rate
was significantly higher in the keishikashakuyakuto group
than in the mepenzolate group [51].
Sasaki and coworkers conducted a multi-center DB-
RCT to investigate the effect of keishikashakuyakuto.
Subjects were randomized to receive either oral treat-
ment with 2.0 g keishikashakuyakuto (EK-60, Kracie and
Co.) three times daily (keishikashakuyakuto group, 124
subjects) or 2.0-g granules containing a low dose (5%) of
keishikashakuyakuto three times daily (low-dose group,
108 subjects) for eight weeks. The final overall improve-
ment rate was not different between the two groups.
However, the percentage of patients with improved ab-
dominal pain was significantly higher in the keishikasha-
kuyakuto group (58% improved moderately or more)
than in the low-dose group (37%) in patients with the
diarrhea-predominant type IBS. Such a difference was
not found in patients with the constipation-predominant
type or alternating type IBS. This study suggests that
keishikashakuyakuto is effective for relieving abdominal
pain in patients with the diarrhea-predominant type
IBS [52].
Among 14 case studies of IBS, most studied the effect-
iveness of keishikashakuyakuto. Others investigated the
effectiveness of other Kampo formulas and suggested
their usefulness. Such prescriptions included saireito,
keihito, heiisan, and daikenchuto. Oka and colleagues
found that, in spite of favorable improvement of abdominal
symptoms such as abdominal pain or diarrhea (percentage
of moderate improvement or more two weeks after treat-
ment, >80%), keishikashakuyakuto was less effective for
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loss (50-60%). They demonstrated that Kampo therapy
became more effective for relieving the extra-colonic
symptoms of IBS patients who did not respond to
keishikashakuyakuto when prescribed based on the
traditional medicine diagnosis, considering the dimen-
sions of “ki-ketsu-sui” or “coldness-heat” balances [53].
Therapeutic mechanisms of keishikashakuyakuto
Peony root and Glycyrrhiza root, both of which are the
main crude ingredients of keishikashakuyakuto, suppress
the neurogenic contractions of the ileum induced by
electrical stimulation and ganglionic-stimulating agents,
such as dimethylphenylpiperazinium and nicotine in
guinea pigs via inhibition of acetylcholine (Ach) release
from cholinergic nerves and inhibition of Ach action on
ileum smooth muscle [54]. Their antispasmodic effect
was also confirmed for the human colon [55]. In addition
to its spasmolytic and smooth muscle-relaxing effects
[56-58], peony root has anti-inflammatory and analgesic
effects and inhibits gastric acid secretion and stress-
induced ulceration [59]. Furthermore, peony root was
demonstrated to have sedative [60] and antidepressant-
like effects in mice [61-66]. The antidepressant-like effect
of peony root could be, at least in part, mediated by
inhibiting monoamine oxidase activity, hypothalamic-
pituitary-adrenal axis activation, oxidative stress, and up-
regulated brain-derived neurotrophic factor [62-66].
Discussion
We reviewed RCTs that evaluated the effects of Kampo
medicines on FGIDs. Clinical trial results have suggested
that several Kampo medicines are useful for relieving
the subjective symptoms of patients with FGIDs, i.e., rik-
kunshito for FD and keishikashakuyakuto for IBS.
In addition to efficacy, these studies suggest several in-
teresting characteristics of Kampo as pharmacotherapy.
First, rikkunshito was effective not only for gastrointes-
tinal symptoms but also for the extra-gastric symptoms
of patients with FD, such as dizziness, coldness in the
lower extremities, or general fatigue. As patients withTable 1 Beneficial effects of Kampo medicines on mind, stres
Effects on brain Effect





Inhibits activities of CRH-producing
neurons.





BDNF, brain-derived neurotrophic factor; CRH, corticotropin-releasing hormone; GI,
nervous system.FGIDs are known to complain of many symptoms that
are not of gastrointestinal origin [67,68], this characteris-
tic of Kampo medicine may be beneficial for improving
the quality of life of these patients. Second, basic re-
search has demonstrated that Kampo medicines have
multiple sites of action to alleviate symptoms. As was
described previously, Kampo medicines act on both the
central nervous system (mind) and the gastrointestinal
tract (body) to relieve symptoms. They also exhibit anti-
stress effects. These multiple actions could be beneficial
for patients with FGID and comorbid psychiatric disor-
ders, patients whose physical symptoms are modulated
by psychological factors such as anxiety or depression,
or patients whose symptoms are exacerbated by psycho-
logical stress (Table 1). Third, Kampo medicines, at
least rikkunshito and keishikshakuyakuto, become
more effective if patients are diagnosed and treated
based on the viewpoint of traditional medicine. This is
reasonable because Kampo medicines were originally
prescribed based on a traditional medicine diagnosis,
e.g. “kyo-sho”, not on the modern medicine diagnosis,
e.g. FD. To accumulate evidence for the efficacy of
Kampo medicine, it is necessary to conduct RCTs to
evaluate its efficacy based on modern medicine diagno-
ses. In the future, however, clinical studies should be
conducted based on both approaches, like the studies
by Miyoshi [5] and Harasawa [6].
Limitations: Case series have suggested that hangeko-
bokuto and hangeshashinto are effective for FD and that
saireito, keihito, heiisan, and daikenchuto are effective
for IBS. Their mechanisms of action are also well studied
and account for their effects. For example, hangekobo-
kuto was demonstrated to facilitate gastric emptying
[10] and decrease the bowel gas [11] of patients with
FD. However, so far, the effects of these Kampo medi-
cines have not been evaluated in RCTs. Further studies
are necessary to determine whether these Kampo medi-
cines are really effective for FGIDs.
Recently, the gastroenterologists Tominaga and Arakawa
published an excellent review article on Kampo for
gastrointestinal disorders [69]. The strengths of theirs, and body in functional gastrointestinal disorders
s on stress Effects on GI tract
ts stress-induced activation
A axis and SNS.
Improves gastric motility dysfunction,








gastrointestinal; HPA, hypothalamic-pituitary-adrenocortical; SNS, sympathetic
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broader range of disorders than we introduced in this
article, including gastroesophageal reflux disorders and
post-operative ileus, and that they described the basic
mechanisms of action of Kampo on the gastrointestinal
tract more precisely than we did. The strengths of our
review article are that we introduced the RCTs and case
series written in Japanese, to which Tominaga and
Arakawa did not refer in their article, because we
thought it important to introduce such pioneering works
and that we described the effects of Kampo on extra-
gastrointestinal tract symptoms and on the central nervous
system and stress systems as well as on the gastrointestinal
tract from the psychosomatic medicine point of view.
Therefore, these two review articles will enable readers to
understand the whole picture of the role of Kampo as a
treatment for FGIDs.Conclusions
This article reviewed the effects of Kampo medicines on
FGIDs, focusing on FD and IBS. Four RCTs suggested
the usefulness of rikkunshito for FD. Two RCTs sug-
gested the usefulness of keishikashakuyakuto for IBS.
These Kampo medicines act on both the brain and the
gastrointestinal tract to alleviate subjective symptoms.
Case series suggest that several other Kampo medicines
are also effective for FGIDs. However, further studies are
necessary to evaluate their efficacy.
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